In this retrospective, observational study, researchers utilized a large US health insurance claims database to assess treatment patterns of patients with Type 2 diabetes initiating GLP-1 receptor agonist therapy with albiglutide or liraglutide.
Medication adherence is an important component of Type 2 diabetes melitus control and treatment; it is associated with improved glycemic control, fewer diabetes-related complications, lower healthcare costs and reduced patient mortality. At the time of publication, there had been no comparative data for albiglutide versus other GLP-1 receptor agonists, such as liraglutide, in a real-world setting.
In this retrospective, claims data-based, observational study, researchers from Optum (MN, USA) and GlaxoSmithKline (PA, USA) utilized a large US health insurance claims database to assess treatment patterns, including adherence and discontinuation rates, among patients initiating GLP-1 receptor agonist therapy with albiglutide or liraglutide during a 6-month period. In a subset of patients, glycemic control was also compared between matched cohorts of commercially insured patients with type 2 diabetes melitus receiving albiglutide or liraglutide.